Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine

Gîlca, Vladimir; Serres, Gaston De; Boulianne, Nicole; Wals, Philippe De; Murphy, Donald G.; Trudeau, Gisele; Deceuninck, Geneviève; Massé, Raymond; Duval, Bernard

doi:10.4161/hv.6.2.10299

Cited by 8 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 26.13% of subjects whose anti-HBs basal levels were ≥100 mIU/ml showed a decrease in antibodies 2-3 years later. This finding supports the decay of antibodies over time since vaccination ( 1 , 27 , 28 ) and once again points to the importance of controlling anti-HBs levels, especially in high-risk groups. Globally, we could not establish any gender or age differences in the basal levels of anti-HBs or in the immunological response to HBV vaccine and booster; other authors arrive at similar conclusions ( 24 , 29 , 30 ).…”

Section: Discussionsupporting

confidence: 79%

Serologic control against hepatitis B virus among dental students of the University of Granada, Spain

Arias-Moliz¹,

Rojas²,

Liébana‐Cabanillas³

et al. 2015

Med Oral

View full text Add to dashboard Cite

BackgroundTo evaluate the immunological situation against hepatitis B virus (HBV) of a cohort of dentistry students, to analyze the behavior of the levels of hepatitis B surface antigen (anti-HBs) after the administration of one or three vaccine doses, and to determine the influence of age and sex on the immune response.Material and MethodsThis retrospective cohort study included students attending the School of Dentistry of the institution where the study was performed from 2005 to 2012 who had completed the public health vaccination calendar for HBV at the age of 12-13. Data on age, sex, basal anti-HBs levels, post-vaccination anti-HBs results and final anti-HBs levels were collected. Comparisons of the basal and final levels, as well as associations regarding age and sex, were performed by means of the Student t and Chi-square tests.ResultsOf the 359 students, 97 (27.02%) had basal antibody concentrations <10 mIU/ml, whereas in 262 the levels of anti-HBs were ≥10 mIU/ml (72.98%). Of the 288 participating students who completed the School´s protocol for immunization, 287 (99.65%) attained a level of protection ≥10 mIU/ml. Globally, there were statistically significant differences between the basal antibody levels and those achieved after administration of the vaccine and booster, but no association with age or sex was observed.ConclusionsAbout 70% of dental students vaccinated as preadolescents had serologic evidence of protection against HBV. Administering a booster is associated with the presence of an excellent immune memory. There is clearly a need to reinforce control of the antibody levels in groups at risk, such as Dentistry students. Key words:Dental students, hepatitis B virus, serologic control.

show abstract

Section: Discussionsupporting

confidence: 79%

Serologic control against hepatitis B virus among dental students of the University of Granada, Spain

Arias-Moliz¹,

Rojas²,

Liébana‐Cabanillas³

et al. 2015

Med Oral

View full text Add to dashboard Cite

show abstract

“…4,5 In pre-licensure clinical trials conducted by vaccine manufacturers, the 0, 1-2 and 6 months schedule was used 4,5 and only a few post-licensure clinical trials assessed the immunogenicity and efficacy of alternative vaccination schedules including a 0, 6 month schedule in 9-13 year-old girls. [6][7][8][9][10] Existing data show that 2 doses of HPV vaccine administered to pre-adolescents induce an immune response which is similar to and even higher than the immune response observed after 3 doses given to [16][17][18][19][20][21][22][23][24][25][26] year-old females. 11 These observations raised the question regarding the number of doses needed when vaccinating pre-adolescent girls.…”

Section: Please Scroll Down For Articlementioning

confidence: 98%

The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine

Gîlca

Sauvageau

Boulianne

et al. 2015

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

This randomized, blinded study evaluated the immunogenicity and safety of a booster dose of Gardasil (qHPV) or Cervarix (bHPV) when administered to 12-13 year-old girls who were vaccinated at the age of 9-10 with 2 doses of qHPV (0-6 months). 366 out of 416 eligible girls participated in this follow-up study. Antibody titers were measured just before and one month post-booster. A Luminex Total IgG assay was used for antibody assessment and results are presented in Liminex Units (LU). Three years post-primary vaccination, 99-100% of subjects had detectable antibodies to 4HPV genotypes included in the qHPV with GMTs varying from 50 to 322 LU depending on genotype. After a booster dose of qHPV, a ≥4 fold increase of antibody titers to genotypes included in the vaccine was observed in 88-98% of subjects. Post-booster GMTs varied from 1666 to 4536 LU depending on genotype. These GMTs were 1.1 to 1.8-fold higher when compared to those observed one month post-second dose. After a booster of bHPV, a ≥4 fold increase of antibody titers to HPV16 and HPV18 was observed in 93-99% of subjects. The anti-HPV16 and HPV18 GMTs were 5458 and 2665 LU, respectively. These GMTs were 1.2 and 1.8 higher than those observed in the qHPV group (both P < 0.01). In bHPV group a 1.4-1.6-fold increase of antibody GMTs to HPV6 and HPV11was also observed (P < 0.001). The safety profile was acceptable for both vaccines. Both qHPV and bHPV increase antibody titers when given as a booster to girls previously vaccinated with 2 doses of qHPV. The magnitude of the immune response after booster is vaccine-dependent and has the same pattern as that reported after primary vaccination with qHPV or bHPV. When given as a booster, both vaccines have an acceptable safety profile. Longer follow-up studies are warranted to assess the need of booster doses.

show abstract

“…Approximately 5-10% of those vaccinated against HBV fail to respond with the development of antibody and moreover, anti-HBs titres decrease over time. Reasons for non-response to HBV vaccination might be multifactorial including host factors such as age, smoking, obesity, gender, and host genetics; and vaccine and vaccination factors such as vaccine type, vaccination dose, injection site, and the time passed after the last vaccination [8,9]. Anti-HBs titre is used to evaluate the efficacy of hepatitis B vaccine and titres of >10 mIU/ml is considered protective [10].…”

Section: Introductionmentioning

confidence: 99%

Post Hepatitis B vaccination sero-conversion among health care workers in the Cape Coast Metropolis of Ghana

et al. 2019

View full text Add to dashboard Cite

Background HBV vaccine is known to offer protection against transmission of HBV infection. Health care workers are mandated to have this vaccination as part of their occupational health safety measures. Post vaccination response data for HCWs in our setting is not available. This study therefore aimed to evaluate the anti-HBs titre levels after Hepatitis B vaccination among HCWs from selected heath facilities in the Cape Coast Metropolis, Ghana. Methods A multicenter (3 selected sites) analytical cross-sectional study involving 711 HCWs was conducted. Five (5mls) of blood samples were collected from each study participant and the serum used for HBV immunological profile testing anti-HBs quantification by ELISA test (Fortress Diagnostics Limited, Northern Ireland, United Kingdom). Data analyses were performed using Stata version 14.0 software (STATA Corp, Texas USA). Results The median age of participants was 29 years (IQR = 26–35 years). Majority (80.9%, n = 575) took their vaccination from Government health facilities compared with 19.1% (n = 136) from private vaccination sources. A total of 7 (3 males and 4 females) were found to be HBsAg positive giving prevalence of 1%. In all, 8.2% (n = 58) of the HCWs had anti-HBs titre levels <10IU/ml giving a sero-protection rate of 91.8%. HCWs who received 3 doses of HBV vaccine were more likely to be sero-protected as compared to those who received only one dose in multivariate analysis (aOR = 3.39, 95%CI: 1.08–10.67), p<0.037). Gender, cigarette smoking and alcohol consumption were not found to be associated with sero-protection. Conclusion There is a high HBV vaccine efficacy among HCWs in the Cape Coast Metropolis of Ghana with higher prevalence of anti-HBs titre level associated with full vaccine dose adherence. Post vaccination antibody titre determination could be an integral part of HBV vaccination protocol for HCWs in Ghana.

show abstract

Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine

Cited by 8 publications

References 15 publications

Serologic control against hepatitis B virus among dental students of the University of Granada, Spain

Serologic control against hepatitis B virus among dental students of the University of Granada, Spain

The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine

Post Hepatitis B vaccination sero-conversion among health care workers in the Cape Coast Metropolis of Ghana

Contact Info

Product

Resources

About